ConductScience.org, home
Papers
API referenceFor AI assistants

Paper39201634

Different Strategies to Overcome Resistance to Proteasome Inhibitors-A Summary 20 Years after Their Introduction.

Tyrna P and 3 others. Int J Mol Sci, 2024. Cited by 12 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. Different Strategies to Overcome Resistance to Proteasome Inhibitors-A Summary 20 Years after Their Introduction. Papers, record 39201634. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39201634

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Different Strategies to Overcome Resistance to Proteasome Inhibitors-A Summary 20 Years after Their Introduction.
PubMed
Journal
Int J Mol Sci
PubMed
Year
2024
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
12
iCite
Relative citation ratio, by iCite
2.11, provisional
iCite
Revised in PubMed
2024-09-03
PubMed

Authors4

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Tyrna PPawełhttps://orcid.org/0000-0003-2341-6976
2Procyk GGrzegorzhttps://orcid.org/0000-0001-8333-7570
3Szeleszczuk ŁŁukaszhttps://orcid.org/0000-0002-5302-3797
4Młynarczuk-Biały IIzabelahttps://orcid.org/0000-0002-5192-6415

Source PubMed

Topics8

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Proteasome InhibitorsMajor topic
Drug Resistance, NeoplasmMajor topic
Multiple MyelomaMajor topic
Humans
Animals
Antineoplastic Agents
Proteasome Endopeptidase Complex
Autophagy

Source PubMed

References142

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
11,429,590Purification of an 11 S regulator of the multicatalytic protease.J Biol Chem1992https://conductscience.org/library/papers/1429590PubMed
228,140,719Phase I/II study of the novel proteasome inhibitor delanzomib (CEP-18770) for relapsed and refractory multiple myeloma.Leuk Lymphoma2017https://conductscience.org/library/papers/28140719PubMed
321,963,883Regulation of p97 in the ubiquitin-proteasome system by the UBX protein-family.Biochim Biophys Acta2012https://conductscience.org/library/papers/21963883PubMed
434,175,021
Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study.
Lancet2021https://conductscience.org/library/papers/34175021PubMed
528,117,417Proteasome inhibitors in cancer therapy.Nat Rev Clin Oncol2017https://conductscience.org/library/papers/28117417PubMed
69,175,783Lactacystin, a specific inhibitor of the proteasome, inhibits human platelet lysosomal cathepsin A-like enzyme.Biochem Biophys Res Commun1997https://conductscience.org/library/papers/9175783PubMed
717,655,704First clinical experience with simvastatin to overcome drug resistance in refractory multiple myeloma.Eur J Haematol2007https://conductscience.org/library/papers/17655704PubMed
827,156,098Multiple functions of p21 in cell cycle, apoptosis and transcriptional regulation after DNA damage.DNA Repair (Amst)2016https://conductscience.org/library/papers/27156098PubMed
923,268,747Therapeutic targeting of cancer cell cycle using proteasome inhibitors.Cell Div2012https://conductscience.org/library/papers/23268747PubMed
1031,955,515NEK2 induces autophagy-mediated bortezomib resistance by stabilizing Beclin-1 in multiple myeloma.Mol Oncol2020https://conductscience.org/library/papers/31955515PubMed
1126,362,997Panobinostat for the Treatment of Multiple Myeloma.Clin Cancer Res2015https://conductscience.org/library/papers/26362997PubMed
1224,833,354Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti-IL-6) in multiple myeloma.Blood2014https://conductscience.org/library/papers/24833354PubMed
1331,406,111Blockade of ubiquitin receptor Rpn13 in plasmacytoid dendritic cells triggers anti-myeloma immunity.Blood Cancer J2019https://conductscience.org/library/papers/31406111PubMed
1431,971,027Heat shock proteins as a new, promising target of multiple myeloma therapy.Expert Rev Hematol2020https://conductscience.org/library/papers/31971027PubMed
159,753,033
Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant.
Br J Haematol1998https://conductscience.org/library/papers/9753033PubMed
1630,104,634The immunoproteasome and thymoproteasome: functions, evolution and human disease.Nat Immunol2018https://conductscience.org/library/papers/30104634PubMed
1724,252,210The resistance mechanisms of proteasome inhibitor bortezomib.Biomark Res2013https://conductscience.org/library/papers/24252210PubMed
1834,571,936Omega-3 Fatty Acids DHA and EPA Reduce Bortezomib Resistance in Multiple Myeloma Cells by Promoting Glutathione Degradation.Cells2021https://conductscience.org/library/papers/34571936PubMed
1928,143,565Disulfiram overcomes bortezomib and cytarabine resistance in Down-syndrome-associated acute myeloid leukemia cells.J Exp Clin Cancer Res2017https://conductscience.org/library/papers/28143565PubMed
2035,377,789Proteasome complexes experience profound structural and functional rearrangements throughout mammalian spermatogenesis.Proc Natl Acad Sci U S A2022https://conductscience.org/library/papers/35377789PubMed

See all 142 references

Cited by9

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 12 citations.

PMIDTitleJournalYearIn PapersSource
42,358,837The Dual Role of Natural Peptides in Cancer Therapy: Anticancer and Immunomodulatory Perspectives.Oncol Res2026https://conductscience.org/library/papers/42358837PubMed
42,356,558Synergistic Molecular Strategies for Targeting the Unfolded Protein Response in Cancer Therapy.Pharmaceuticals (Basel)2026https://conductscience.org/library/papers/42356558PubMed
41,652,637Dysregulation of post-translational modifications in glioma: advances in pathological mechanisms and clinical targeting strategies.J Transl Med2026https://conductscience.org/library/papers/41652637PubMed
41,441,334Azidohomoalanine (AHA) Metabolic Labeling Reveals Unique Proteomic Insights into Protein Synthesis and Degradation in Response to Bortezomib Treatment.Proteomes2025https://conductscience.org/library/papers/41441334PubMed
41,011,245Small Molecule Protease Inhibitors as Model Peptidomimetics.Pharmaceuticals (Basel)2025https://conductscience.org/library/papers/41011245PubMed
40,859,966Synergistic Mechanisms of Traditional Chinese Medicine and Proteasome Inhibitors in Multiple Myeloma Therapy: A Comprehensive Review.Drug Des Devel Ther2025https://conductscience.org/library/papers/40859966PubMed
40,291,513Targeting Active Microglia Alleviates Distal Edge of Proton Radiation-induced Neural Damage.Adv Radiat Oncol2025https://conductscience.org/library/papers/40291513PubMed
39,852,147Prognostic Value of PSMB5 and Correlations with LC3II and Reactive Oxygen Species Levels in the Bone Marrow Mononuclear Cells of Bortezomib-Resistant Multiple Myeloma Patients.Curr Issues Mol Biol2025https://conductscience.org/library/papers/39852147PubMed
39,653,983REGγ-mediated Barrier Disruption and NF-κB Activation Aggravates Intestinal Inflammation in Necrotizing Enterocolitis.Inflammation2025https://conductscience.org/library/papers/39653983PubMed

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/39201634

GET https://conductscience.org/api/papers/v1/39201634/references?page=2

API referenceFor AI assistants